News

As per Bloomberg estimates, Mankind Pharma's consolidated revenue for the first quarter is expected to rise year-on-year to ...
The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.
Jefferies said it expects Mankind Pharma's first and second quarters to be steep quarters. It said the company's prescription drugs (Rx) growth is set to normalise in the second half.
Jefferies anticipates that the first and second quarters will be pivotal for Mankind Pharma, with India Rx growth normalising in the second half of the fiscal.
Background: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, performs a reduction in the all-cause mortality and cardiovascular mortality in type 2 diabetes mellitus (T2DM) patients compared ...
The House passed the “One Big Beautiful Bill Act” on July 3, which includes sweeping changes to healthcare and some pharma-related provisions.
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. | Chinese ...
Pharma FDA weighs regulatory action on argenx's Vyvgart Hytrulo amid reports of 'severe worsening' of disease By Angus Liu Jul 1, 2025 11:19am argenx U.S. FDA Vyvgart subcutaneous drug delivery ...